| 000 | 02275nam a22001817a 4500 | ||
|---|---|---|---|
| 001 | CUHAS/BP/3000268/T/15 | ||
| 008 | 210809b |||||||| |||| 00| 0 eng d | ||
| 100 |
_a Panga, Neema _dCUHAS/BP/3000268/T/15 _920953 _eUndergraduate Ethical Clearance Certificate No. 932/2019 |
||
| 245 | _a Adverse Drug Reaction Among Patients Who Received Vincristine and Actinomycin D fro Treatment of Wilms Tumour at Bugando Medical Centre. | ||
| 260 |
_aMwanza, Tanzania _bCatholic University of Health and Allied Sciences [CUHAS - Bugando] _bPhone: +255 28 298 3384 : _b Fax: +255 28 298 3386 : _b Email: vc@bugando.ac.tz : _b Website: www.bugando.ac.tz : _c ©30.08.2019 |
||
| 300 | _a x; 18 Pages | ||
| 300 | _aIncludes References and Appendices | ||
| 520 | _aAbstract: Background: Wilms tumour is an embryonal tumour of the kidney and mostly it affects children and is the second most common childhood malignancy affecting children under 5 years. Actinomycin D and vincristine have been observed to be the most effective drugs for management of Wilms tumour. Methodology: Retrospective cross-sectional hospital-based study conducted at oncology department in Bugando medical centre, Tanzania. Study included 80 Wilms tumours patients’ files from January 2010 to December 2018 selected by consecutive sampling. Data was filled in excel and analysed using STATA version 13. Results and Discussion: The age group affected mostly was 1-5 years. The most chemotherapy prescribed was combination of Actinomycin D and Vincristine (58.75%), vincristine (40%) and Actinomycin D (1.25%). Adverse reactions observed were anemia (41.25%), vomiting (7.5%), neutropenia and eye discharge. About 43.73% showed no documentation on the adverse drugs reactions. Conclusion and Recommendations: Adverse drug reactions associated with the use of vincristine were anemia, vomiting and neutropenia. Combined therapy was associated with anemia, eye discharge and vomiting. Actinomycin D was associated with anemia. There must be a documentation of the adverse drug reactions by the health practitioners to make a better choice during a therapeutic plan. | ||
| 600 |
_xPharmacy _926693 |
||
| 600 |
_xPharmacology _930211 |
||
| 700 |
_aKongola, G. W. M _920952 |
||
| 942 |
_2ddc _cCR |
||
| 999 |
_c20947 _d20947 |
||